文献速递眼底病与葡萄膜炎小儿眼科与斜弱视

DIGIROP-Screen:优化早产儿视网膜病变筛查的临床决策支持工具

Development and validation of a new clinical decision support tool to optimize screening for retinopathy of prematurity.
PubMed 文献 · Br J Ophthalmol · 2021-05-12

基于瑞典国家ROP登记库24-30周早产儿数据开发DIGIROP-Screen预测工具,在三个国际队列外部验证。该工具在出生时和矫正胎龄8周时以100%灵敏度识别需治疗的ROP,特异性分别为53.1%和60.5%,外部验证特异性相似(46.3%和53.5%)。

要点

  • DIGIROP-Screen在24-30周早产儿中识别需治疗ROP的灵敏度达100%,可安全减少不必要筛查。
  • 出生时特异性53.1%,矫正胎龄8周累积特异性60.5%,外部验证分别为46.3%和53.5%。
  • 与其他ROP模型相比,DIGIROP-Screen的灵敏度和特异性相等或更高。

核心结论

  • DIGIROP-Screen可安全识别24-30周早产儿中不需要ROP筛查的婴儿,灵敏度和特异性等于或高于其他模型。

研究设计与样本

  • 开发队列来自瑞典国家ROP登记库,纳入胎龄24-30周婴儿6991例;外部验证采用三个国际队列共1241例。
  • 采用多变量逻辑回归,在出生后6-14周龄间验证预测因子,包括出生特征、首次诊断ROP的状态和年龄及关键交互作用。

主要发现

  • 开发队列中287例(4.1%)需ROP治疗,验证队列中49例(3.9%)需治疗。
  • 开发队列出生时特异性53.1%,矫正胎龄8周累积特异性60.5%;验证队列相应为46.3%和53.5%。
  • 验证队列中一例严重畸形婴儿被错误分类为不需筛查,其余婴儿在6-14周龄灵敏度为100%。
  • 其他已发表模型的灵敏度范围为88.5%至100%,特异性范围为9.6%至45.2%。

关键数值与推荐

  • 以100%灵敏度为约束条件,开发队列出生时特异性53.1%,矫正胎龄8周累积特异性60.5%。
  • 验证队列应用相同截断值,出生时特异性46.3%,矫正胎龄8周累积特异性53.5%。

临床怎么用

  • DIGIROP-Screen利用易获得的出生和ROP筛查数据,可辅助临床决策以减少不需要治疗的早产儿筛查。
  • 该工具应在任何新队列中验证,若未通过验证可使用相同统计方法针对特定临床环境进行修改。

局限性

  • 验证队列中一例严重畸形婴儿被错误分类为不需筛查。
  • 研究人群为胎龄24-30周早产儿,并在欧洲和北美人群中测试,其他人群需进一步验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND/AIMS: Prematurely born infants undergo costly, stressful eye examinations to uncover the small fraction with retinopathy of prematurity (ROP) that needs treatment to prevent blindness. The aim was to develop a prediction tool (DIGIROP-Screen) with 100% sensitivity and high specificity to safely reduce screening of those infants not needing treatment. DIGIROP-Screen was compared with four other ROP models based on longitudinal weights. METHODS: Data, including infants born at 24-30 weeks of gestational age (GA), for DIGIROP-Screen development (DevGroup, N=6991) originate from the Swedish National Registry for ROP. Three international cohorts comprised the external validation groups (ValGroups, N=1241). Multivariable logistic regressions, over postnatal ages (PNAs) 6-14 weeks, were validated. Predictors were birth characteristics, status and age at first diagnosed ROP and essential interactions. RESULTS: ROP treatment was required in 287 (4.1%)/6991 infants in DevGroup and 49 (3.9%)/1241 in ValGroups. To allow 100% sensitivity in DevGroup, specificity at birth was 53.1% and cumulatively 60.5% at PNA 8 weeks. Applying the same cut-offs in ValGroups, specificities were similar (46.3% and 53.5%). One infant with severe malformations in ValGroups was incorrectly classified as not needing screening. For all other infants, at PNA 6-14 weeks, sensitivity was 100%. In other published models, sensitivity ranged from 88.5% to 100% and specificity ranged from 9.6% to 45.2%. CONCLUSIONS: DIGIROP-Screen, a clinical decision support tool using readily available birth and ROP screening data for infants born GA 24-30 weeks, in the European and North American populations tested can safely identify infants not needing ROP screening. DIGIROP-Screen had equal or higher sensitivity and specificity compared with other models. DIGIROP-Screen should be tested in any new cohort for validation and if not validated it can be modified using the same statistical approaches applied to a specific clinical setting.

来源:Br J Ophthalmol,查看原文。版权归原作者所有。

引用

  1. Pivodic A, Johansson H, Smith LEH, et al. Development and validation of a new clinical decision support tool to optimize screening for retinopathy of prematurity. Br J Ophthalmol. 2021. PMID: 33980506. doi:10.1136/bjophthalmol-2020-318719

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。